<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190059</url>
  </required_header>
  <id_info>
    <org_study_id>VIT-001-TOR</org_study_id>
    <secondary_id>139150</secondary_id>
    <nct_id>NCT01190059</nct_id>
  </id_info>
  <brief_title>Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation</brief_title>
  <acronym>HELP</acronym>
  <official_title>Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XVIVO Perfusion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XVIVO Perfusion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of ex vivo lung perfusion (EVLP) will allow for a secondary evaluation technique for
      donor lungs that fail to meet standard acceptability criteria. This advanced assessment might
      lead to increased utilization rates of donor lungs and improved outcomes after lung
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human donor lungs that do not meet the standard clinical criteria for donor lung utilization
      but fit into the study inclusion criteria will be retrieved from the donor using current
      donor lung retrieval techniques.

      These lungs will be brought to the study transplant center to be re-assessed by the
      transplant team. The lungs will be physiologically assessed during ex vivo perfusion with
      Steen Solution. Perfusion of these lungs will be performed using Steen solution with the
      addition of methylprednisolone, heparin and antibiotics. With respect to the decision of lung
      utilization those organs with a delta pO2 (Δ pO2 = Pulmonary vein pO2 - pulmonary artery pO2)
      during ex vivo perfusion assessment &gt; 350mmHg, good lung compliance, and a favorable opinion
      of the transplant surgeon will be considered transplantable. Lungs will be excluded for
      transplantation: if the Δ pO2 is less than 350mmHg or if they demonstrate &gt;10% deterioration
      in any of the following functional parameters: pulmonary vascular resistance (PVR), dynamic
      compliance or airway pressures. Lungs will also be excluded if they are deemed unsuitable
      based on the clinical judgment of the lung transplant surgeon.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PGD scores in the first 72 hours after lung transplantation.</measure>
    <time_frame>72 hours</time_frame>
    <description>Immediate lung function is one of the key factors in determining the impact of donor lung quality, therefore the PGD score within 72 hrs was selected as the primary endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30 day Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality at 30 days post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extra-corporeal membrane oxygenation use</measure>
    <time_frame>30 days</time_frame>
    <description>If the patient needed to be placed on extra-corporeal membrane oxygenation after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchial complications</measure>
    <time_frame>30 days</time_frame>
    <description>To see if there was an increased risk for bronchial complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator duration</measure>
    <time_frame>30 days</time_frame>
    <description>How long was the patient on the ventilator after lung transplantation and was there an increased time on ventilator for the patient after EVLP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit length of stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Time in the hospital</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>EVLP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ex vivo lung perfusion with Steen Solution™</intervention_name>
    <description>The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.</description>
    <arm_group_label>EVLP Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for donor lung:

          1. Recipient to undergo a single or bilateral Lung Transplantation

          2. Last donor PaO2/FiO2 ≤ 300mmHg

          3. Poor oxygenation and/or poor lung compliance is the primary reason for unsuitability

          4. Absence of pneumonia, persistent purulent secretion on bronchoscopy or significant
             mechanical trauma

        Exclusion Criteria:

          1. Infection

          2. Aspiration

          3. Significant mechanical lung injury - contusion

          4. Infectious diseases : HIV, Hepatitis B and C, HTLV &amp; Syphilis

          5. Malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaf Keshavjee, MD,MSc,FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto-Toronto General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Pierre AF, Sekine Y, Hutcheon MA, Waddell TK, Keshavjee SH. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg. 2002 Mar;123(3):421-7; discussion, 427-8.</citation>
    <PMID>11882811</PMID>
  </reference>
  <reference>
    <citation>de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med. 2003 Feb 15;167(4):490-511. Review.</citation>
    <PMID>12588712</PMID>
  </reference>
  <reference>
    <citation>Cypel M, Rubacha M, Yeung J, Hirayama S, Torbicki K, Madonik M, Fischer S, Hwang D, Pierre A, Waddell TK, de Perrot M, Liu M, Keshavjee S. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant. 2009 Oct;9(10):2262-9. doi: 10.1111/j.1600-6143.2009.02775.x. Epub 2009 Aug 6.</citation>
    <PMID>19663886</PMID>
  </reference>
  <reference>
    <citation>D.M. Karamanou, H.R. Walden, S. Bean, et al. The Effect of Ex-Vivo Perfusion on the Inflammatory Profile of the Donor Lung. J Heart Lung Transplant 2010:Vol. 29, Issue 2, Supplement, Page S165.</citation>
  </reference>
  <reference>
    <citation>Inci I, Ampollini L, Arni S, Jungraithmayr W, Inci D, Hillinger S, Leskosek B, Vogt P, Weder W. Ex vivo reconditioning of marginal donor lungs injured by acid aspiration. J Heart Lung Transplant. 2008 Nov;27(11):1229-36. doi: 10.1016/j.healun.2008.07.027. Epub 2008 Oct 1.</citation>
    <PMID>18971096</PMID>
  </reference>
  <reference>
    <citation>Steen S, Sjöberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. Lancet. 2001 Mar 17;357(9259):825-9.</citation>
    <PMID>11265950</PMID>
  </reference>
  <reference>
    <citation>Ingemansson R, Eyjolfsson A, Mared L, Pierre L, Algotsson L, Ekmehag B, Gustafsson R, Johnsson P, Koul B, Lindstedt S, Lührs C, Sjöberg T, Steen S. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg. 2009 Jan;87(1):255-60. doi: 10.1016/j.athoracsur.2008.09.049.</citation>
    <PMID>19101308</PMID>
  </reference>
  <reference>
    <citation>Steen S, Ingemansson R, Eriksson L, Pierre L, Algotsson L, Wierup P, Liao Q, Eyjolfsson A, Gustafsson R, Sjöberg T. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo. Ann Thorac Surg. 2007 Jun;83(6):2191-4.</citation>
    <PMID>17532422</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <last_update_submitted>November 12, 2010</last_update_submitted>
  <last_update_submitted_qc>November 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Shaf Keshavjee</name_title>
    <organization>University of Toronto-Toronto General Hospital</organization>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Lung Transplantation</keyword>
  <keyword>Transplantation Lung</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

